The importance of selecting a proper biological milieu for protein corona analysis in vitro: Human plasma versus human serum

International Journal of Biochemistry and Cell Biology

Volumn 75, Issue , 2016, Pages 188-195

  Mirshafiee, Vahid ^a   Kim, Raehyun ^a   Mahmoudi, Morteza ^b,c   Kraft, Mary L ^a,d  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Human plasma; Human serum; Nanoparticle; Opsonins; Protein corona

Indexed keywords

ALPHA FIBRINOGEN; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 CHAIN A; APOLIPOPROTEIN A4; APOLIPOPROTEIN B100; APOLIPOPROTEIN C1; APOLIPOPROTEIN C1 CHAIN A; APOLIPOPROTEIN C3; APOLIPOPROTEIN C3 CHAIN A; APOLIPOPROTEIN E; APOLIPOPROTEIN E CHAIN A; APOLIPOPROTEIN E3; APOLIPOPROTEIN E3 CHAIN A; FIBRINOGEN; FIBRINOGEN CHAIN A; GELSOLIN; GLYCOPROTEIN; HISTIDINE RICH GLYCOPROTEIN; KININOGEN; LIPOPROTEIN; LIPOPROTEIN GLN 1; PROAPOLIPOPROTEIN; PROTEIN CORONA; SERUM ALBUMIN; SILICA NANOPARTICLE; TETRANECTIN; UNCLASSIFIED DRUG; NANOPARTICLE; SILICON DIOXIDE;

3T3 CELL LINE; ANIMAL CELL; ARTICLE; CHEMICAL INTERACTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; INTERNALIZATION; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN INTERACTION; RAW 264.7 CELL LINE; SERUM; SURFACE CHARGE; SURFACE PROPERTY; TANDEM MASS SPECTROMETRY; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; NIH 3T3 CELL LINE; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; MICE; NANOPARTICLES; NIH 3T3 CELLS; PLASMA; PROTEIN CORONA; RAW 264.7 CELLS; SERUM; SILICON DIOXIDE;

EID: 84954286669     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2015.11.019     Document Type: Article

References (56)

1. P. Aggarwal, J.B. Hall, C.B. McLeland, M.A. Dobrovolskaia, and S.E. McNeil Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy Adv. Drug Deliv. Rev. 61 2009 428 437
2. R. Ahmad Khanbeigi, T.F. Abelha, A. Woods, O. Rastoin, R.D. Harvey, M.-C. Jones, and et al. Surface chemistry of photoluminescent F8BT conjugated polymer nanoparticles determines protein corona formation and internalization by phagocytic cells Biomacromolecules 16 2015 733 742
3. A. Albanese, P.S. Tang, and W.C.W. Chan The effect of nanoparticle size, shape, and surface chemistry on biological systems Annu. Rev. Biomed. Eng. 14 2012 1 16
4. D.C. Altieri, R. Bader, P.M. Mannucci, and T.S. Edgington Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen J. Cell Biol. 107 1988 1893 1900
5. J. Ashby, S. Pan, and W. Zhong Size and surface functionalization of iron oxide nanoparticles influence the composition and dynamic nature of their protein corona ACS Appl. Mater. Interfaces 6 2014 15412 15419
6. C.F. Borgognoni, M. Mormann, Y. Qu, M. Schäfer, K. Langer, C. Öztürk, and et al. Reaction of human macrophages on protein corona covered TiO2 nanoparticles Nanomed. Nanotechnol. Biol. Med. 11 2015 275 282
7. G.J. Cannon, and J.A. Swanson The macrophage capacity for phagocytosis J. Cell Sci. 101 1992 907 913
8. T. Cedervall, I. Lynch, M. Foy, T. Berggård, S.C. Donnelly, G. Cagney, and et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles Angew. Chem. Int. Ed. 46 2007 5754 5756
9. T. Cedervall, I. Lynch, S. Lindman, T. Berggård, E. Thulin, H. Nilsson, and et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles Proc. Natl. Acad. Sci. U.S.A. 104 2007 2050 2055
10. A.B. Chinen, C.M. Guan, and C.A. Mirkin Spherical nucleic acid nanoparticle conjugates enhance G-quadruplex formation and increase serum protein interactions Angew. Chem. Int. Ed. 54 2015 527 531
11. A. Cifuentes-Rius, H. de Puig, J.C.Y. Kah, S. Borros, and K. Hamad-Schifferli Optimizing the properties of the protein corona surrounding nanoparticles for tuning payload release ACS Nano 7 2013 10066 10074
12. Q. Dai, Y. Yan, C.-S. Ang, K. Kempe, M.M.J. Kamphuis, S.J. Dodds, and et al. Monoclonal antibody-functionalized multilayered particles: targeting cancer cells in the presence of protein coronas ACS Nano 9 2015 2876 2885
13. M.A. Dobrovolskaia, A.K. Patri, J. Zheng, J.D. Clogston, N. Ayub, P. Aggarwal, and et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles Nanomed. Nanotechnol. Biol. Med. 5 2009 106 117
14. M. Elsabahy, and K.L. Wooley Design of polymeric nanoparticles for biomedical delivery applications Chem. Soc. Rev. 41 2012 2545 2561
15. O.C. Farokhzad, J. Cheng, B.A. Teply, I. Sherifi, S. Jon, P.W. Kantoff, and et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc. Natl. Acad. Sci. U.S.A. 103 2006 6315 6320
16. K. Furumoto, K.-I. Ogawara, S. Nagayama, Y. Takakura, M. Hashida, K. Higaki, and et al. Important role of serum proteins associated on the surface of particles in their hepatic disposition J. Controll. Release 83 2002 89 96
17. I. García, A. Sánchez-Iglesias, M. Henriksen-Lacey, M. Grzelczak, S. Penadés, and L.M. Liz-Marzán Glycans as biofunctional ligands for gold nanorods: stability and targeting in protein-rich media J. Am. Chem. Soc. 137 2015 3686 3692
18. M. Hadjidemetriou, Z. Al-Ahmady, M. Mazza, R.F. Collins, K. Dawson, and K. Kostarelos In vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesicles ACS Nano 9 2015 8142 8156
19. Y. Ishihama, Y. Oda, T. Tabata, T. Sato, T. Nagasu, J. Rappsilber, and et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein Mol. Cell. Proteom. 4 2005 1265 1272
20. H.J. Issaq, Z. Xiao, and T.D. Veenstra Serum and plasma proteomics Chem. Rev. 107 2007 3601 3620
21. S.M. Janib, A.S. Moses, and J.A. MacKay Imaging and drug delivery using theranostic nanoparticles Adv. Drug Deliv. Rev. 62 2010 1052 1063
22. J.A. Kim, A. Salvati, C. Aberg, and K.A. Dawson Suppression of nanoparticle cytotoxicity approaching in vivo serum concentrations: limitations of in vitro testing for nanosafety Nanoscale 6 2014 14180 14184
23. J. Lazarovits, Y.Y. Chen, E.A. Sykes, and W.C.W. Chan Nanoparticle-blood interactions: the implications on solid tumour targeting Chem. Commun. 51 2015 2756 2767
24. A. Lesniak, F. Fenaroli, M.P. Monopoli, C. Åberg, K.A. Dawson, and A. Salvati Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells ACS Nano 6 2012 5845 5857
25. A. Lesniak, A. Salvati, M.J. Santos-Martinez, M.W. Radomski, K.A. Dawson, and C. Åberg Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency J. Am. Chem. Soc. 135 2013 1438 1444
26. M. Lundqvist, J. Stigler, T. Cedervall, T. Berggård, M.B. Flanagan, I. Lynch, and et al. The evolution of the protein corona around nanoparticles: a test study ACS Nano 5 2011 7503 7509
27. M. Lundqvist, J. Stigler, G. Elia, I. Lynch, T. Cedervall, and K.A. Dawson Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts Proc. Natl. Acad. Sci. U.S.A. 105 2008 14265 14270
28. M. Mahmoudi, I. Lynch, M.R. Ejtehadi, M.P. Monopoli, F.B. Bombelli, and S. Laurent Protein-nanoparticle interactions: opportunities and challenges Chem. Rev. 111 2011 5610 5637
29. M. Mahmoudi, S.N. Saeedi-Eslami, M.A. Shokrgozar, K. Azadmanesh, M. Hassanlou, H.R. Kalhor, and et al. Cell "vision": complementary factor of protein corona in nanotoxicology Nanoscale 4 2012 5461 5468
30. E. Mahon, A. Salvati, F. Baldelli Bombelli, I. Lynch, and K.A. Dawson Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery" J. Controll. Release 161 2012 164 174
31. D. Maiolo, P. Bergese, E. Mahon, K.A. Dawson, and M.P. Monopoli Surfactant titration of nanoparticle-protein corona Anal. Chem. 86 2014 12055 12063
32. V. Mirshafiee, R. Kim, S. Park, M. Mahmoudi, and M.L. Kraft Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake Biomaterials 75 2016 295 304
33. V. Mirshafiee, M. Mahmoudi, K. Lou, J. Cheng, and M.L. Kraft Protein corona significantly reduces active targeting yield Chem. Commun. 49 2013 2557 2559
34. M.P. Monopoli, D. Walczyk, A. Campbell, G. Elia, I. Lynch, F. Baldelli Bombelli, and et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles J. Am. Chem. Soc. 133 2011 2525 2534
35. D.F. Moyano, M. Goldsmith, D.J. Solfiell, D. Landesman-Milo, O.R. Miranda, D. Peer, and et al. Nanoparticle hydrophobicity dictates immune response J. Am. Chem. Soc. 134 2012 3965 3967
36. D.F. Moyano, K. Saha, G. Prakash, B. Yan, H. Kong, M. Yazdani, and et al. Fabrication of corona-free nanoparticles with tunable hydrophobicity ACS Nano 8 2014 6748 6755
37. S. Nagayama, K.-i. Ogawara, Y. Fukuoka, K. Higaki, and T. Kimura Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics Int. J. Pharm. 342 2007 215 221
38. D.J. O'Connell, F.B. Bombelli, A.S. Pitek, M.P. Monopoli, D.J. Cahill, and K.A. Dawson Characterization of the bionano interface and mapping extrinsic interactions of the corona of nanomaterials Nanoscale 7 2015 15268 15276
39. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760
40. W.C. Raschke, S. Baird, P. Ralph, and I. Nakoinz Functional macrophage cell lines transformed by abelson leukemia virus Cell 15 1978 261 267
41. U. Sakulkhu, L. Maurizi, M. Mahmoudi, M. Motazacker, M. Vries, A. Gramoun, and et al. Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats Nanoscale 6 2014 11439 11450
42. A. Salvati, A.S. Pitek, M.P. Monopoli, K. Prapainop, F.B. Bombelli, D.R. Hristov, and et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface Nat. Nanotechnol. 8 2013 137 143
43. K. Shapero, F. Fenaroli, I. Lynch, D.C. Cottell, A. Salvati, and K.A. Dawson Time and space resolved uptake study of silica nanoparticles by human cells Mol. Biosyst. 7 2011 371 378
44. D.J. Sobczynski, P. Charoenphol, M.J. Heslinga, P.J. Onyskiw, K. Namdee, A.J. Thompson, and et al. Plasma protein corona modulates the vascular wall interaction of drug carriers in a material and donor specific manner PLoS One 9 2014 e107408
45. A. Sobota, A. Strzelecka-Kiliszek, E. Gładkowska, K. Yoshida, K. Mrozińska, and K. Kwiatkowska Binding of IgG-opsonized particles to FcγR is an active stage of phagocytosis that involves receptor clustering and phosphorylation J. Immunol. 175 2005 4450 4457
46. B.E. Steinberg, and S. Grinstein Analysis of macrophage phagocytosis: quantitative assays of phagosome formation and maturation using high-throughput fluorescence microscopy Methods Mol. Biol. 531 2009 45 56
47. S. Takasaki, F. Emling, and L. Leive Variants deficient in phagocytosis of latex beads isolated from the murine macrophagelike cell line J774 J. Cell Biol. 98 1984 2198 2203
48. L. Tang, T.M. Fan, L.B. Borst, and J. Cheng Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates ACS Nano 6 2012 3954 3966
49. S. Tenzer, D. Docter, J. Kuharev, A. Musyanovych, V. Fetz, R. Hecht, and et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology Nat. Nanotechnol. 8 2013 772 781
50. C. Trezzini, T.W. Jungi, P. Kuhnert, and E. Peterhans Fibrinogen association with human monocytes: evidence for constitutive expression of fibrinogen receptors and for involvement of Mac-1 (CD18, CR3) in the binding Biochem. Biophys. Res. Commun. 156 1988 477 484
51. D. Walczyk, F.B. Bombelli, M.P. Monopoli, I. Lynch, and K.A. Dawson What the cell "sees" in bionanoscience J. Am. Chem. Soc. 132 2010 5761 5768
52. C.D. Walkey, and W.C.W. Chan Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment Chem. Soc. Rev. 41 2012 2780 2799
53. L. Wang, W. Zhao, M.B. O'Donoghu, and W. Tan Fluorescent nanoparticles for multiplexed bacteria monitoring Bioconjug. Chem. 18 2007 297 301
54. J. Xie, S. Lee, and X. Chen Nanoparticle-based theranostic agents Adv. Drug Deliv. Rev. 62 2010 1064 1079
55. M.M. Yallapu, N. Chauhan, S.F. Othman, V. Khalilzad-Sharghi, M.C. Ebeling, S. Khan, and et al. Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles Biomaterials 46 2015 1 12
56. Z. Zhang, C. Wang, Y. Zha, W. Hu, Z. Gao, Y. Zang, and et al. Corona-directed nucleic acid delivery into hepatic stellate cells for liver fibrosis therapy ACS Nano 9 2015 2405 2419